Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | M6PR | P20645 | 2/20 | 0.44 |
| ▸ | MGAM | O43451 | 4/20 | 0.40 |
| ▸ | SI | P14410 | 4/20 | 0.40 |
| ▸ | G6PD | P11413 | 2/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.38 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12070982 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL15215703 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL15121661 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL2505909 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL15273797 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL2233716 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL24605082 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL1832193 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL15273793 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL13509342 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1876234-B1 | BETA-GALACTOSIDE-ALPHA2,3-SIALYLTRANSFERASE, GENE ENCODING THE SAME, AND PROCESS FOR PRODUCTION OF THE SAME | JAPAN TOBACCO INC (JP) | 2013-07-24 | — | — | EP | disclosed |
| EP-2434018-A2 | A novel beta-galactoside-alpha2, 3-sialyltransferase, a gene encoding thereof, and a method for producing thereof | Japan Tobacco Inc. (JP) | 2012-03-28 | — | — | EP | disclosed |
| US-20120070863-A1 | NOVEL BETA-GALACTOSIDE-ALPHA2,3-SIALYLTRANSFERASE, A GENE ENCODING THEREOF, AND A METHOD FOR PRODUCING THEREOF | YAMAMOTO TAKESHI (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8030043-B2 | β-galactoside-α2,3-sialyltransferase, a gene encoding thereof, and a method for producing thereof | JAPAN TOBACCO INC. (JP) | 2011-10-04 | — | — | US | disclosed |
| EP-1079824-B1 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF | RES DEV FOUNDATION (US) | 2011-08-31 | — | — | EP | disclosed |
| US-7985435-B2 | Triterpene compositions and methods for use thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2011-07-26 | — | — | US | disclosed |
| US-20100291631-A1 | Novel Beta-Galactoside-Alpha 2,3-Sialyltransferase, a Gene Encoding Thereof, and a Method for Producing Thereof | JAPAN TOBACCO INC. (JP) | 2010-11-18 | — | — | US | disclosed |
| US-20100189824-A1 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF | ARNTZEN CHARLES J | 2010-07-29 | — | — | US | disclosed |
| US-7670632-B2 | Triterpene compositions and methods for use thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1079824-A4 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF | RES DEV FOUNDATION (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20030039705-A1 | Triterpene compositions and methods for use thereof | RESEARCH DEVELOPMENT FOUNDATION | 2003-02-27 | — | — | US | disclosed |
| US-20030031738-A1 | Triterpene compositions and methods for use thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2003-02-13 | — | — | US | disclosed |
| US-6444233-B1 | ANTITUMOR AGENTS | RESEARCH DEVELOPMENT FOUNDATION | 2002-09-03 | — | — | US | disclosed |
| EP-1079824-A1 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF | RESEARCH DEVELOPMENT FOUNDATION (a Nevada corporation) (US) | 2001-03-07 | — | — | EP | disclosed |
| US-6165500-A | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2000-12-26 | — | — | US | disclosed |
| WO-1999059578-A1 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 1999-11-25 | — | — | WO | disclosed |
| EP-0725144-A1 | Process for the preparation of glycosides using glycosidases from ciliates | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-08-07 | — | — | EP | disclosed |
| EP-0475160-B1 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 1996-02-14 | — | — | EP | disclosed |
| EP-0475160-A1 | Preparation for drug application in minute droplet form | Cevc, Gregor, Prof. Dr. (DE) | 1992-03-18 | — | — | EP | disclosed |
| WO-1992003122-A1 | PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS | CEVC GREGOR (DE) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100189824-A1 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF | OSTC, ACACA, NFATC1 | M6PR 862/4885MGAM 549/4885SI 16/4885 |
| US-20030031738-A1 | Triterpene compositions and methods for use thereof | OSTC, ACACA, NFATC1 | M6PR 862/4885MGAM 549/4885SI 16/4885 |
| US-20030039705-A1 | Triterpene compositions and methods for use thereof | BAX, CASP3, ACACA | M6PR 1748/4885MGAM 2237/4885SI 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.